Peter Block, MD, FACC, and Deepak L. Bhatt, MD, MPH, FACC, discuss the Thursday meeting highlights from TCT 2015, including the SAPIEN 3 trial and the BRAVO 3 trial. View full TCT 2015 meeting coverage at ACC.org/TCT and watch all the video coverage on ACC’s YouTube page.
I am a practicing interventional cardiologist, interested in the cardiovascular evaluation and management of athletes, running the spectrum from the weekend warrior to those who play professionally. You might ask “how” or “why” someone who opens blocked arteries would get involved in professional ice hockey. In comparison to the other major league sports in our country, hockey falls a distant fourth in terms of things like revenues, salaries, fan interest, TV markets and organizational infrastructure. Nonetheless, in December 1992, a patient of ours was awarded a franchise as the NHL expanded and we were asked to be involved in the medical care. My first experience with professional hockey was at the training camp in the summer of 1993 in Peterborough, Canada, with the late coach Roger Neilson. The rest is history. Continue reading
“Biomedical innovation represents the best and enables the worst of our health care system,” began Alan Weil, editor-in-chief of Health Affairs, at the opening of the publication’s briefing on a recent issue, which featured panel discussions with featured authors. A majority of the authors’ findings were overwhelmingly positive for the future of medicine, including one study which showed the evolution of biotechnology and its impact on health care over the past 35 years. Ronald A. Evens, MD, author of the study, remarked “biotech molecules have dramatically altered heath care for many unmet medical needs across all medical disciplines.”
During the panel on medical devices, I presented the recently published Health Affairs paper, “Transcatheter Valve Therapy Registry Is A Model For Medical Device Innovation And Surveillance,” showing that advances in biotechnology go beyond the molecules to include the actual systems that track and record who receives biotech devices and how they respond to them. In the paper, we took a close look at the STS/ACC TVT Registry, which is a model of collaboration among professional societies, the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, hospitals, patients, and the medical device industry. Continue reading
This post was authored by Valentin Fuster, PhD, MD, MACC, editor of Journal of the American College of Cardiology.
First, I want to compliment Laura Mauri, MD, and her colleagues for conducting the landmark Dual Antiplatelet Therapy (DAPT) trial, which was presented yesterday at the American Heart Association’s Scientific Sessions in Chicago.
Recent guidelines have recommend that patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) discontinue dual-antiplatelet therapy – a combination of aspirin and another platelet inhibitor (e.g., clopidogrel) – within six months to one year. Nevertheless, the U.S. Food and Drug Administration and some clinicians have been concerned about the long-term impact of stents and dual-antiplatelet therapy duration on the adverse outcome of stent thrombosis. Continue reading
This post was authored by Xiushui (Mike) Ren, MD, affiliate member of the ACC.
A near equal proportion of cardiologists and cardiothoracic surgeons attended this year’s ACC/AATS 2014 Heart Valve Summit in Chicago, IL from September 18 – 20.
Conference Co-Director Robert O. Bonow, MD, MACC, kicked-off the meeting with an update of the 2014 ACC/American Heart Association guideline for the management of patients with valvular heart disease. For all valves, the guideline committee emphasized using stages to categorize valve disease, analogous to stages of heart failure. Stage A represents patients at risk for valve disease, such as bicuspid aortic valve or mitral valve prolapse; stage B represents patients with mild to moderate valve dysfunction; stage C represents patients with severe asymptomatic valve disease; stage D represents patients with severe symptomatic valve disease. Continue reading
This post was authored by Patrick T. O’Gara, MD, FACC, incoming president of the ACC.
The academic year begins July 1, a time when medical trainees begin their careers as physicians and enter fields with skills that are not yet refined. The idea that an influx of inexperienced trainees might adversely impact patient outcomes, including death and major morbidity, at this time of year is commonly referred to as the “July effect.” The existence of the “July effect” has long been documented in medical disciplines outside of cardiology, where high rates of medical errors, complications and mortality are experienced. Continue reading
“…and where would I hear the murmur?” – Anonymous participant at a recent Championing Care meeting
All of us, having alternately taught and been taught all of our lives, are educators, reveling in that never-ending cycle of falling behind and catching up again, reproduced the world over.
Tactically, our post-graduate continuing medical education has been structured as “onion-skinning,” our substantial pre-existing knowledge base repetitively veneered with a thin layer of highly specific new content applied intermittently. In practical terms, a group of interventionists come together and receive late-breaking information about interventional cardiology, echocardiographers gaining similar information regarding their imaging modality, that content being tailored specifically to what is a highly select audience, a horizontally homogenous group consuming specific information updates in a periodic fashion. Continue reading